EPI Health is now a Novan Company. The EP Group today announced the acquisition of EPI Health, LLC by Novan, Inc. 

EPI Health is a leading company in the US dermatology sector with an established sales force and commercial team with existing, deep market relationships across the dermatology community. Novan is a specialty dermatology pharmaceutical company focused on developing therapeutic products for skin diseases. The Company is leveraging its core platform of nitric oxide-based science and clinical translation expertise to bring new medicines to market. Novan’s lead candidate, berdazimer gel 10.3%, performed well in a phase 3 study for the treatment of molluscum contagiosum. The company plans to submit a New Drug Application (NDA) to the FDA in the fourth quarter of this year.

Following the acquisition, the company, known as EPI Health, a Novan Company, will employ approximately 100 staff with over 300 years of combined excellence in dermatology product development, commercialization, and sales.

“EPI Health has established itself as a leading commercial dermatology company and I am excited about the synergies this transaction offers both Companies. As of today, we are now a fully integrated specialty dermatology company with a robust pipeline of development candidates and have the commercial infrastructure to realize the full value each program brings,” commented Paula Brown Stafford, Chairman and Chief Executive Officer of Novan. “I am pleased to welcome EPI Health to the Novan family.” 

“The combined entity has the opportunity to be a force multiplier for both companies, creating a pharmaceutical engine that has the capabilities to discover innovative therapies, develop them through the clinic and through a proven commercial platform bring medications to patients with unmet needs,” added John Donofrio, President of EPI Health and now Chief Operating Officer of Novan.